http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 03:12:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Overweight/26743335.html <p>JPMorgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Overweight rating and a price target of $27.00.</p><p>The analyst comments: “We are initiating coverage of BridgeBio Oncology (BBOT) with an Overweight rating and a December 2027 price target of $27. In our view, BridgeBio Oncology’s differentiated next-generation precision oncology approach targeting the RAS and PI3Kα pathways creates an attractive early entry point as we await additional early-stage data. We have a positive outlook on using specific next-generation ON / OFF inhibitors to target mutant KRAS in both on and off states in cancers, which is http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Overweight/26743335.html Wed, 08 Jul 2026 03:12:42 -0400 BBOT http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Overweight/26743335.html <p>JPMorgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Overweight rating and a price target of $27.00.</p><p>The analyst comments: “We are initiating coverage of BridgeBio Oncology (BBOT) with an Overweight rating and a December 2027 price target of $27. In our view, BridgeBio Oncology’s differentiated next-generation precision oncology approach targeting the RAS and PI3Kα pathways creates an attractive early entry point as we await additional early-stage data. We have a positive outlook on using specific next-generation ON / OFF inhibitors to target mutant KRAS in both on and off states in cancers, which is http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Overweight/26743335.html Wed, 08 Jul 2026 03:12:42 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Ben+Yong/26736868.html si-local-file:///var/storage/secattach/20260706/26736868.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Ben+Yong/26736868.html Mon, 06 Jul 2026 18:00:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Beltran+Pedro/26736869.html si-local-file:///var/storage/secattach/20260706/26736869.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Beltran+Pedro/26736869.html Mon, 06 Jul 2026 18:00:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Elmelech+Idan/26736872.html si-local-file:///var/storage/secattach/20260706/26736872.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Elmelech+Idan/26736872.html Mon, 06 Jul 2026 18:00:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Cobo+Marc/26736875.html si-local-file:///var/storage/secattach/20260706/26736875.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Cobo+Marc/26736875.html Mon, 06 Jul 2026 18:00:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Chen+Bihua/26736087.html si-local-file:///var/storage/secattach/20260706/26736087.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jul+01++Filed+by%3A+Chen+Bihua/26736087.html Mon, 06 Jul 2026 16:35:00 -0400 BBOT http://www.streetinsider.com/New+Coverage/Oppenheimer+Assumes+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Outperform/26669922.html <p>Oppenheimer analyst Mazahir Alimohamed assumes coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Outperform rating and a price target of $22.00.</p><p>The analyst commented: "We are assuming coverage of BridgeBio Oncology Therapeutics (BBOT) with an Outperform rating and $22 price target. BBOT is advancing a portfolio of oral small molecules against RAS and PI3Kα oncogenes, led by BBO-8520 (KRAS G12C ON/ OFF inhibitor), BBO-11818 (pan-KRAS ON/OFF inhibitor), and BBO-10203 (novel RAS:PI3Kα breaker). We view '8520 as potential best-in-class G12C agent with a 65% ORR and differentiated liver-safety profile in NSCLC; '10203's hyperglycemia-free profile and '11818's first pan-KRAS PR also http://www.streetinsider.com/New+Coverage/Oppenheimer+Assumes+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Outperform/26669922.html Mon, 22 Jun 2026 07:35:15 -0400 BBOT http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Assumes+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Outperform/26669922.html <p>Oppenheimer analyst Mazahir Alimohamed assumes coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Outperform rating and a price target of $22.00.</p><p>The analyst commented: "We are assuming coverage of BridgeBio Oncology Therapeutics (BBOT) with an Outperform rating and $22 price target. BBOT is advancing a portfolio of oral small molecules against RAS and PI3Kα oncogenes, led by BBO-8520 (KRAS G12C ON/ OFF inhibitor), BBO-11818 (pan-KRAS ON/OFF inhibitor), and BBO-10203 (novel RAS:PI3Kα breaker). We view '8520 as potential best-in-class G12C agent with a 65% ORR and differentiated liver-safety profile in NSCLC; '10203's hyperglycemia-free profile and '11818's first pan-KRAS PR also http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Assumes+BridgeBio+Oncology+Therapeutics%2C+In+%28BBOT%29+at+Outperform/26669922.html Mon, 22 Jun 2026 07:35:15 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+MCCORMICK+FRANK/26666970.html si-local-file:///var/storage/secattach/20260618/26666970.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+MCCORMICK+FRANK/26666970.html Thu, 18 Jun 2026 16:59:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Tipirneni+Praveen+P./26667018.html si-local-file:///var/storage/secattach/20260618/26667018.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Tipirneni+Praveen+P./26667018.html Thu, 18 Jun 2026 16:59:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Kelleher+Raymond+J./26666956.html si-local-file:///var/storage/secattach/20260618/26666956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Kelleher+Raymond+J./26666956.html Thu, 18 Jun 2026 16:57:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Lebowitz+Peter+F/26666959.html si-local-file:///var/storage/secattach/20260618/26666959.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Lebowitz+Peter+F/26666959.html Thu, 18 Jun 2026 16:57:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Chen+Bihua/26666945.html si-local-file:///var/storage/secattach/20260618/26666945.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Chen+Bihua/26666945.html Thu, 18 Jun 2026 16:56:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Bauer+Jake/26666924.html si-local-file:///var/storage/secattach/20260618/26666924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Bauer+Jake/26666924.html Thu, 18 Jun 2026 16:54:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Kumar+Neil/26666916.html si-local-file:///var/storage/secattach/20260618/26666916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+Jun+16++Filed+by%3A+Kumar+Neil/26666916.html Thu, 18 Jun 2026 16:53:00 -0400 BBOT http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Press+Releases/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html <ul type="disc"><li><em>Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs</em></li><li><em>Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor</em></li><li><em>Clinical readouts expected in the second half of 2026 across all three programs</em></li><li><em>Cash runway expected to fund operations into 2028<br></br><br></br></em></li></ul> <p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.</p> http://www.streetinsider.com/Globe+Newswire/BBOT+Reports+First+Quarter+2026+Financial+Results+and+Update+on+Corporate+Progress/26479158.html Tue, 12 May 2026 17:03:00 -0400 A.35552990 BBOT O.00074346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+May+10++Filed+by%3A+Beltran+Pedro/26477954.html si-local-file:///var/storage/secattach/20260512/26477954.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+May+10++Filed+by%3A+Beltran+Pedro/26477954.html Tue, 12 May 2026 16:12:00 -0400 BBOT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+May+10++Filed+by%3A+Elmelech+Idan/26477980.html si-local-file:///var/storage/secattach/20260512/26477980.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BridgeBio+Oncology+Thera++For%3A+May+10++Filed+by%3A+Elmelech+Idan/26477980.html Tue, 12 May 2026 16:12:00 -0400 BBOT http://www.streetinsider.com/Press+Releases/BridgeBio+Oncology+Therapeutics+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26477557.html <p align="justify">SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.</p> <p align="justify">The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $7.66 per share, the closing price of BBOT’s common stock as reported by Nasdaq http://www.streetinsider.com/Press+Releases/BridgeBio+Oncology+Therapeutics+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26477557.html Tue, 12 May 2026 16:05:00 -0400 BBOT